• Matthew R Woeste, Prejesh Philips, Michael E Egger, Charles R Scoggins, Kelly M McMasters, and Martin Robert C G RCG http://orcid.org/0000-0002-5537-3387 Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville,.
• Division of Surgical Oncology, Department of Surgery, University of Louisville, Louisville, Kentucky.
• J Surg Oncol. 2020 Jun 1; 121 (8): 1298-1305.

BackgroundPeritoneal carcinomatosis of colorectal adenocarcinoma (CRC) origin is common and is the second-most frequent cause of death in colorectal cancer. There is survival benefit to surgical resection plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with metastatic CRC. However, there remains controversy between oxaliplatin (Oxali) and mitomycin C (MMC), as the agent of choice.MethodsA review of our 285 patients prospective HIPEC database from July 2007 to May 2018 identified 48 patients who underwent cytoreductive surgery plus HIPEC with MMC or Oxali. Patients were stratified based on preoperative and postoperative peritoneal cancer indices (PCI). The primary outcomes of survival and progression-free survival were compared.ResultsType of HIPEC chemotherapy was not found to be predictive of overall survival. Preoperative PCI (P = .04), preoperative response to chemotherapy (P = .0001), and postoperative PCI (P = .05) were predictive for overall survival.ConclusionsMMC or Oxali based HIPEC chemotherapy are both safe and effective for the management of peritoneal only metastatic CRC. Both perfusion therapies should be considered with all patients receiving modern induction chemotherapy.© 2020 Wiley Periodicals, Inc.

36 keywords...

hide…